Advancedsignaling

Cell Communication Gone Wrong: Signaling Defects in Cancer

Overview

Where the cancer hallmarks guide describes what cancer cells can do, this guide explains how broken communication lets them do it. You will trace normal signaling — growth factors binding receptors, relay cascades like Ras-MAPK, and the stop signals of contact inhibition — then see each step's cancerous corruption: receptors stuck on, pathways locked active, autocrine loops where cells stimulate themselves, and the loss of anchorage and density dependence. The focus throughout is signaling logic: how cells normally talk, listen, and obey — and what happens when the conversation breaks.

Learning objectives

  • Describe normal growth-factor signaling from receptor to nucleus.
  • Explain how receptor and Ras mutations lock pathways in the ON state.
  • Define autocrine signaling and its role in tumors.
  • Explain loss of contact inhibition, density dependence, and anchorage dependence.

Structure and function

PartStructureFunction
Growth factorSignaling protein (e.g., EGF, PDGF) instructing cells to divide; binds specific surface receptors.The 'divide' message in normal tissue — produced by neighbors, received by the target cell.
Receptor tyrosine kinase (RTK)Membrane receptor (e.g., EGFR) that phosphorylates itself and recruits relay proteins when growth factor binds.The antenna: converts extracellular signal into intracellular phosphorylation cascade.
Ras-MAPK pathwayRelay cascade: Ras (GTPase switch) → Raf → MEK → ERK, carrying the signal to the nucleus.The transmission line: each step amplifies; ERK enters the nucleus and switches on proliferation genes.
Autocrine loopCell secreting a growth factor for which it has the receptor — stimulating itself.Short-circuit: the cell becomes its own growth-factor supplier, needing no neighbors' permission.
Contact inhibitionNormal cells stopping division when touching neighbors (density-dependent inhibition).The crowd brake: mediated by cell-cell adhesion signals; lost in cancer, letting tumors pile up.
Anchorage dependenceNormal cells requiring attachment to extracellular matrix to divide.The location brake: detached normal cells arrest or die (anoikis); cancer cells divide unattached.
Diagram guide

Diagram: a normal cell (left) receiving growth factor from a neighbor → RTK → Ras-MAPK cascade → nucleus ('divide' order); contact inhibition icons show crowded cells with stop signals, and an attached cell on matrix fibers. A cancer cell (right) shows four corruptions in red: 1) mutated RTK firing without ligand, 2) Ras locked in GTP-ON state, 3) autocrine loop (cell secreting and receiving its own growth factor, circular arrow), 4) cells piled in a heap ignoring contact inhibition + a detached cell dividing in fluid (anchorage independence).

Normal signaling: message, antenna, relay

Healthy proliferation is a conversation. A neighbor secretes growth factor (EGF, PDGF); it binds the cell's receptor tyrosine kinase (EGFR); the receptor dimerizes, autophosphorylates, and recruits adaptors; Ras — a GTPase switch — loads GTP and activates the MAPK cascade (Raf → MEK → ERK); ERK enters the nucleus and switches on cyclin D and other proliferation genes. Each step is gated: receptors need ligand, Ras hydrolyzes GTP to switch off, phosphatases reverse phosphorylations. The default is silence; division requires a complete, verified message.

The signaling chain

Growth factor → RTK → Ras-GTP → MAPK cascade → nucleus → cyclin D → division. Every arrow is a potential failure point — and cancer exploits nearly all of them.

Corruption 1: stuck antennas and jammed switches

Cancer mutates the chain into permanence. EGFR mutations or amplifications make receptors fire without ligand — the antenna stuck transmitting. Ras mutations (common across cancers) destroy its GTPase activity: Ras loads GTP but can't hydrolyze it, freezing the switch ON and driving the MAPK cascade continuously. B-Raf mutations do the same one step down. The result: the nucleus receives a constant 'divide' order no external signal sent. Targeted drugs (EGFR inhibitors, B-Raf/MEK inhibitors) work by jamming these specific stuck components — precision medicine aimed at the corrupted link.

Why Ras was 'undruggable' for decades

Ras's smooth surface offered no drug-binding pocket, frustrating chemists for 30 years. Recent KRAS-G12C inhibitors finally exploit a mutant-specific crevice — a landmark in targeting the previously untargetable.

Corruption 2: autocrine loops — self-stimulation

Some tumor cells secrete the very growth factors their own receptors detect — autocrine signaling. A glioma cell making its own PDGF while expressing PDGF receptors needs no neighbor's permission to divide; the loop is closed, self-sustaining, and invisible to the tissue's normal controls. Normal cells use autocrine signaling legitimately (e.g., immune cells amplifying responses), but in tumors it becomes independence: the cell manufactures both the message and the mailbox, cutting the tissue out of the decision entirely.

Autocrine vs paracrine

Paracrine: signal to NEIGHBORS (normal tissue coordination). Autocrine: signal to SELF (normal in some contexts, pathological when driving unregulated growth). The distance of the message defines the term.

Corruption 3: ignoring the stop signals

Normal cells obey two social brakes. Density-dependent inhibition: crowded cells, sensing neighbors through cadherin contacts, activate pathways (like Hippo) that halt division — the dish stops at a monolayer. Anchorage dependence: cells must grip the extracellular matrix via integrins to divide; detached cells undergo anoikis (homelessness-triggered apoptosis). Cancer cells lose both: they pile into heaps in culture, divide floating in blood or lymph (enabling metastasis), and ignore Hippo signaling. Losing the brakes matters as much as jamming the accelerator — a car with both failures can't stop.

Two brakes, both cut

Contact inhibition = 'stop, we're crowded' (lost → tumors pile up). Anchorage dependence = 'stop, you're detached' (lost → cells survive and divide in transit, enabling metastasis). Metastasis requires the second loss.

Therapies that target the conversation

Because these corruptions are specific, drugs can target them: monoclonal antibodies block overactive receptors (trastuzumab vs HER2), kinase inhibitors jam mutant pathway components (EGFR, B-Raf, MEK inhibitors), and anti-angiogenic drugs intercept VEGF messages tumors send to vessels. The principle: normal cells don't depend on the corrupted loop, so blocking it hurts tumors selectively. Signaling knowledge doesn't just explain cancer — it draws the drug targets, which is why this guide's pathway details are clinical, not academic.

Companion diagnostics

These drugs work only when the specific corruption is present — hence genetic testing of tumors before treatment. 'EGFR-mutant lung cancer' is a diagnosis defined by the broken signaling component, treated with the drug that jams exactly that component.

Key points

  • Normal: growth factor → RTK → Ras-MAPK → nucleus; each step gated, default is silence.
  • Cancer corrupts the chain: ligand-independent receptors (EGFR), GTP-locked Ras, mutant B-Raf — constant 'divide' orders.
  • Autocrine loops let tumor cells supply their own growth factors — self-stimulation independent of tissue.
  • Lost brakes: contact/density inhibition (Hippo) and anchorage dependence (anoikis) both fail, enabling piling and metastasis.
  • Targeted therapies (antibodies, kinase inhibitors) jam the specific corrupted links — signaling biology drawn as drug targets.

Common misconceptions

✗ Myth: Cancer cells divide because they receive too many growth signals.

✓ Truth: Often they receive none — their receptors fire without ligand or their Ras is locked ON. The corruption is internal and constitutive, not excessive external signaling. That's why removing growth factors doesn't stop them.

✗ Myth: Contact inhibition and anchorage dependence are the same thing.

✓ Truth: Contact inhibition is about crowding (stop when touching neighbors); anchorage dependence is about attachment (stop when detached from matrix). Different signals, different pathways — and cancer must defeat both, the second being essential for metastasis.

✗ Myth: Targeted therapies work on all cancers of an organ.

✓ Truth: They work only on tumors carrying the specific molecular corruption (e.g., EGFR-mutant lung cancers). Without the target, the drug has nothing to jam — hence genetic testing before treatment, not organ-based prescribing.

Practice questions

Q1. A Ras protein that cannot hydrolyze GTP will:
  1. Remain permanently in the active, signal-transmitting state
  2. Be unable to bind GTP at all
  3. Block the receptor from binding growth factor
  4. Trigger immediate apoptosis
Answer: A.

Ras is a GTPase switch: GTP-bound = ON, GDP-bound = OFF. Oncogenic mutations destroy the GTPase activity, freezing Ras in the GTP-bound ON state — the MAPK cascade fires continuously without any growth factor.

Q2. Autocrine signaling in tumors is dangerous because:
  1. It signals to distant organs
  2. The cell stimulates its own division, bypassing tissue-level control
  3. It requires no receptors
  4. It only works at night
Answer: B.

A cell secreting growth factor for its own receptors closes the loop internally — no neighbor's permission needed. This self-sufficiency is one of the hallmarks: the tissue's regulatory conversation is cut out entirely.

Q3. Loss of anchorage dependence helps cancer cells specifically by:
  1. Making them divide faster in tissue
  2. Letting them survive and divide while detached, enabling metastatic travel
  3. Increasing their mutation rate
  4. Blocking apoptosis from DNA damage
Answer: B.

Normal detached cells undergo anoikis; anchorage-independent cancer cells survive in blood/lymph and divide without matrix attachment — the prerequisite for leaving the primary tumor and colonizing distant sites.

Click a question to reveal the answer and explanation.

Frequently asked questions

Why is mutant Ras so hard to turn off compared to a normal receptor?

Normal Ras self-inactivates by hydrolyzing GTP to GDP; oncogenic mutations destroy this GTPase activity, so Ras stays GTP-loaded and signaling permanently. A receptor at least needs ligand (or can be blocked); locked Ras is downstream of every receptor-level intervention — the signal is already inside.

How does losing anchorage dependence enable metastasis?

Metastasis requires cells to survive detached — traveling through blood/lymph without matrix attachment. Normal cells undergo anoikis (detachment-triggered apoptosis) when homeless. Anchorage-independent cancer cells survive the journey, extravasate, and colonize distant sites. No anchorage loss, no metastasis.

What's the difference between a growth factor and an oncogene product?

A growth factor is the normal extracellular message (e.g., EGF). An oncogene product is a corrupted signaling component (mutant Ras, overactive EGFR) that mimics or amplifies the message without regulation. One is the legitimate signal; the other is the broken receiver stuck on.

Why do EGFR inhibitors fail once Ras is mutated downstream?

Blocking the receptor stops the signal at the antenna — but mutant Ras generates the signal internally, downstream of the blockade. The pathway is activated below the drug's point of action, so inhibition upstream is irrelevant. Therapy must target at or below the corrupted link.